What analysts say:
- Buy, sell, or hold?: Analysts strongly back Danaher, with 17 of 19 rating it a buy and the remainder rating it a hold. Analysts like Danaher better than competitor 3M Company overall. Analysts still rate the stock a moderate buy, but they are a bit more wary about it compared with three months ago.
- Revenue Forecasts: On average, analysts predict $4.47 billion in revenue this quarter. That would represent a rise of 40.1% from the year-ago quarter.
- Wall Street Earnings Expectations: The average analyst estimate is earnings of $0.70 per share. Estimates range from $0.68 to $0.73.
What our community says:
CAPS All-Stars are solidly backing the stock with 96.4% assigning it an "outperform" rating. The community at large backs the All-Stars with 95.9% giving it a rating of "outperform." Fools are bullish on Danaher and haven't been shy with their opinions lately, logging 120 posts in the past 30 days. Even with a robust four out of five stars, Danaher's CAPS rating falls a little short of the community's upbeat outlook.
Danaher's profit has risen year over year by an average of 69.7% over the past five quarters. Revenue has now gone up for three straight quarters. The company upped its gross margin by 2.8 percentage points in the last quarter. Revenue rose 12.1% while cost of sales rose 5.8% to $1.77 billion from a year earlier.
For all our Danaher-specific analysis, including earnings and beyond, add Danaher to My Watchlist.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Time to Get Greedy or Fearful With Danaher Corporation's Stock?
Analyzing the investment proposition for the industrial stock that's really a medical technology company.
After Disappointing Earnings, Is Danaher Corporation Still Worth Investing In?
The highly rated company has uncharacteristically disappointed investors with its dental segment, but what does that mean for the investment thesis?
There's More Than Meets the Eye to Danaher Corporation
Why investors should look at the company differently and give the stock a positive re-rating.